Aclarion (ACON) Lytham Partners Fall 2026 Investor Conference summary

Market opportunity and technology

• NOCISCAN platform uses AI-powered detection of biomarkers to identify spinal pain sources, targeting a $32 billion global market opportunity with 141% year-over-year volume growth in early 2026.

• Private payer approvals in England and expanding physician referrals and commercial support in the U.S. signal strong commercial momentum.

• 266 million people globally suffer from chronic low back pain, with 330,000 spinal surgeries annually in the U.S. at high costs and low success rates.

• NOCISCAN offers a non-invasive, objective, and cost-effective alternative to traditional discograms, reducing pain and radiation exposure.

• Intellectual property is robust, with over 64 issued and pending patents worldwide.

Clinical evidence and trials

• The CLARITY Trial, a national randomized control trial, is underway with 11 active sites and aims to drive payer and physician adoption.

• The Gornet Trial showed a 97% surgical success rate when NOCISCAN-positive discs were treated, compared to 54% otherwise.

• CLARITY Trial will enroll 300 patients, measuring outcomes at multiple intervals up to 24 months, with both blinded and unblinded cohorts.

• Additional ongoing trials are validating NOCISCAN's correlation to gold-standard discography and comparing efficacy to other imaging modalities.

Commercial strategy and financials

• U.K. market adoption is accelerating, with three of the four largest payers covering NOCISCAN and a dedicated commercial director driving growth.

• U.S. strategy includes transitioning from Category III to Category I CPT codes and leveraging key opinion leaders for societal endorsement.

• $16 million in cash as of June 30, 2026, provides a runway into 2027, supporting ongoing trials and expansion.

• Clean capital structure with no debt, no preferred shares, and no near-term warrant overhang.